Orphan Drug Designation Granted for rHuEPO for Multiple Myeloma

XTL Biopharmaceuticals announced that its rHuEPO (recombinant human erythropoietin) drug has been granted an orphan drug designation by the FDA for the treatment of multiple myeloma blood cancer. rHuEPO is currently in preparations for Phase 2 clinical trials. An orphan drug designation is limited in connection with illnesses that affect less than 200,000 people a year. In order to encourage the development of treatments of these diseases, regulatory authorities provide benefits and incentives for the developers.

rHuEPO is a genetically engineered version of a natural hormone produced by the kidneys.

For more information call +972-9-955-7080 or email: ir@xtlbio.com.